Literature DB >> 34854950

Identification of prognostic genes in the pancreatic adenocarcinoma immune microenvironment by integrated bioinformatics analysis.

Haolan Wang1, Liqing Lu1, Xujun Liang1, Yongheng Chen2,3.   

Abstract

PURPOSE: Pancreatic adenocarcinoma (PAAD) is one of the most common causes of death among solid tumors, and its pathogenesis remains to be clarified. This study aims to elucidate the value of immune/stromal-related genes in the prognosis of PAAD through comprehensive bioinformatics analysis based on the immune microenvironment and validated in Chinese pancreatic cancer patients.
METHODS: Gene expression profiles of pancreatic cancer patients were obtained from TCGA database. Differentially expressed genes (DEGs) were identified based on the ESTIMATE algorithm. Gene co-expression networks were constructed using WGCNA. In the key module, survival analysis was used to reveal the prognostic value. Subsequently, we performed functional enrichment analysis to construct a protein-protein interaction (PPI) network. The relationship between tumor immune infiltration and hub genes was analyzed by TIMER and CIBERSORT. Finally, it was validated in the GEO database and in tissues of Chinese pancreatic cancer patients.
RESULTS: In the TCGA pancreatic cancer cohort, a low immune/stromal score was associated with a good prognosis. After bioinformatic analysis, 57 genes were identified to be significantly associated with pancreatic cancer prognosis. Among them, up-regulation of four genes (COL6A3, PLAU, MMP11 and MMP14) indicated poor prognosis and was associated with multiple immune cell infiltration. IHC results showed that PLAU protein levels from Chinese pancreatic cancer tissues were significantly higher than those from adjacent non-tumor tissues and were also associated with tumor TNM stage and lymph node metastasis.
CONCLUSION: In conclusion, this study demonstrates that PLAU may serve as a new diagnostic and therapeutic target, which is highly expressed in Chinese pancreatic cancer tissues and associated with lymph node metastasis.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Bioinformatics analysis; Immune microenvironment; Pancreatic adenocarcinoma; Prognosis

Mesh:

Substances:

Year:  2021        PMID: 34854950     DOI: 10.1007/s00262-021-03110-3

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  50 in total

Review 1.  The pancreas cancer microenvironment.

Authors:  Christine Feig; Aarthi Gopinathan; Albrecht Neesse; Derek S Chan; Natalie Cook; David A Tuveson
Journal:  Clin Cancer Res       Date:  2012-08-15       Impact factor: 12.531

2.  Targeting the Microenvironment to Overcome Gemcitabine Resistance in Pancreatic Cancer.

Authors:  Eileen S Carpenter; Nina G Steele; Marina Pasca di Magliano
Journal:  Cancer Res       Date:  2020-08-01       Impact factor: 12.701

Review 3.  Regulation and modulation of antitumor immunity in pancreatic cancer.

Authors:  Joshua Leinwand; George Miller
Journal:  Nat Immunol       Date:  2020-08-17       Impact factor: 25.606

4.  Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy.

Authors:  Mara H Sherman; Ruth T Yu; Dannielle D Engle; Ning Ding; Annette R Atkins; Herve Tiriac; Eric A Collisson; Frances Connor; Terry Van Dyke; Serguei Kozlov; Philip Martin; Tiffany W Tseng; David W Dawson; Timothy R Donahue; Atsushi Masamune; Tooru Shimosegawa; Minoti V Apte; Jeremy S Wilson; Beverly Ng; Sue Lynn Lau; Jenny E Gunton; Geoffrey M Wahl; Tony Hunter; Jeffrey A Drebin; Peter J O'Dwyer; Christopher Liddle; David A Tuveson; Michael Downes; Ronald M Evans
Journal:  Cell       Date:  2014-09-25       Impact factor: 41.582

5.  Identification of cluster of differentiation molecule-associated microRNAs as potential therapeutic targets for gastrointestinal cancer immunotherapy.

Authors:  Hanyu Zhang; Mingxing Li; Parham Jabbarzadeh Kaboli; Huijiao Ji; Fukuan Du; Xu Wu; Yueshui Zhao; Jing Shen; Lin Wan; Tao Yi; Qinglian Wen; Xiang Li; Chi Hin Cho; Jing Li; Zhangang Xiao
Journal:  Int J Biol Markers       Date:  2021-03-31       Impact factor: 2.659

6.  American Cancer Society's report on the status of cancer disparities in the United States, 2021.

Authors:  Farhad Islami; Carmen E Guerra; Adair Minihan; K Robin Yabroff; Stacey A Fedewa; Kirsten Sloan; Tracy L Wiedt; Blake Thomson; Rebecca L Siegel; Nigar Nargis; Robert A Winn; Lisa Lacasse; Laura Makaroff; Elvan C Daniels; Alpa V Patel; William G Cance; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2021-12-08       Impact factor: 508.702

Review 7.  Tumor microenvironment participates in metastasis of pancreatic cancer.

Authors:  Bo Ren; Ming Cui; Gang Yang; Huanyu Wang; Mengyu Feng; Lei You; Yupei Zhao
Journal:  Mol Cancer       Date:  2018-07-30       Impact factor: 27.401

Review 8.  Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment.

Authors:  Chin-King Looi; Felicia Fei-Lei Chung; Chee-Onn Leong; Shew-Fung Wong; Rozita Rosli; Chun-Wai Mai
Journal:  J Exp Clin Cancer Res       Date:  2019-04-15

Review 9.  Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons.

Authors:  Qijie Zhao; Yu Jiang; Shixin Xiang; Parham Jabbarzadeh Kaboli; Jing Shen; Yueshui Zhao; Xu Wu; Fukuan Du; Mingxing Li; Chi Hin Cho; Jing Li; Qinglian Wen; Tao Liu; Tao Yi; Zhangang Xiao
Journal:  Front Immunol       Date:  2021-03-30       Impact factor: 7.561

Review 10.  Mirage or long-awaited oasis: reinvigorating T-cell responses in pancreatic cancer.

Authors:  Michael Brandon Ware; Bassel F El-Rayes; Gregory B Lesinski
Journal:  J Immunother Cancer       Date:  2020-08       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.